Crescent Biopharma Conference Call Summary Company Overview - **Company**: Crescent Biopharma - **Focus**: Advancing life-transforming therapies for cancer treatment - **Market Potential**: Positioned in a market exceeding $100 billion, focusing on next-generation immuno-oncology (IO) therapies, including bispecifics, antibody-drug conjugates (ADCs), and standard care combinations [2][8] Key Products and Pipeline - **CR-001**: A PD-1 VEGF bispecific antibody, expected to be a best-in-class IO backbone - **ADC Portfolio**: Includes CR-002 (PD-L1 Topo ADC) and CR-003 (integrin beta-6 Topo ADC) - **Partnership**: Collaboration with Kelun-Biotech to develop CR-001 in Greater China and in-license CR-003 outside China [6][8] Clinical Development Strategy - **Clinical Trials**: Plans to initiate at least four clinical trials in 2026, with data expected in Q1 2027 - **Funding**: Secured $185 million PIPE, providing financial runway into 2028 to support clinical milestones [8][90] Competitive Positioning - **Differentiation**: CR-001 aims to improve upon existing PD-1 VEGF therapies by enhancing stability and concentration, with a production concentration of 150 mg/ml compared to 10 mg/ml for ivonescimab [11][12] - **Global Development Focus**: Initiating trials in the U.S., Europe, and APAC, addressing translatability issues between Chinese and Western patient populations [13][20] Anticipated Data and Catalysts - **Upcoming Data**: Expecting updates from HARMONi-2, HARMONi-6, and HARMONi-3 studies, which may provide insights into overall survival (OS) and progression-free survival (PFS) [32][34] - **Learning Opportunities**: Data from these studies will inform the development of CR-001 and its positioning against competitors like KEYTRUDA [34][36] ADC Strategy - **Combination Approach**: Focus on rationally designed ADCs targeting thoracic, GI, GynOnc, and head and neck cancers, with plans for synergistic combinations with CR-001 [52][55] - **Independent Value**: Each ADC (CR-002 and CR-003) is expected to have independent value, with potential for both monotherapy and combination therapy development [71][84] Financial Position - **Balance Sheet**: As of September 30, the company reported $246 million pro forma, ensuring funding through 2028 for clinical milestones [90] Conclusion - **Strategic Vision**: Crescent Biopharma is positioned to leverage its innovative therapies and partnerships to capture significant market opportunities in the oncology space, with a clear focus on generating clinical data and establishing a robust pipeline for future growth [2][8][90]

CytomX Therapeutics Conference Call Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Focus**: Development of masked biologics technology, specifically targeting cancer therapies [2][3] Key Industry Insights - **Technology**: CytomX has pioneered the field of masked biologics, allowing for targeted drug delivery to tumor cells while minimizing effects on healthy tissues [2][3] - **Clinical Programs**: The company is currently focused on two clinical programs, with the lead program being a masked EpCAM antibody-drug conjugate (ADC) [3][4] Core Product Insights - **Lead Product**: CX-2051, a masked ADC targeting EpCAM, which is highly expressed in various solid tumors, particularly colorectal cancer (CRC) [5][6] - **Target Rationale**: EpCAM is a compelling target due to its high expression in solid tumors, but previous attempts to target it have faced toxicity issues. CytomX believes its masking technology can mitigate these toxicities [5][6][7] Clinical Data Highlights - **Colorectal Cancer Statistics**: CRC has 1.9 million cases globally and is the second leading cause of cancer death, with a five-year survival rate of only 13% in metastatic cases [12] - **Phase 1 Data**: In a difficult-to-treat patient population (average of four prior therapies), CX-2051 showed a 28% objective response rate and 94% disease control rate, with a progression-free survival (PFS) of 5.8 months [14][19] - **Safety Profile**: The drug did not exhibit classic EpCAM-related toxicities such as pancreatitis or liver toxicity. The main adverse effect observed was grade 3 diarrhea in 21% of patients [15][16] Future Development Plans - **Expansion of Clinical Trials**: CytomX plans to expand the enrollment to approximately 100 patients across three active doses (7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg) to better understand efficacy and safety [19][20] - **Regulatory Pathway**: The company aims to discuss potential registrational studies with the FDA by mid-2027, focusing on late-line CRC treatment [37][38] Competitive Landscape - **Market Position**: CytomX believes it has a strong competitive position in the ADC space for CRC, with a compelling drug profile compared to other ADCs targeting CRC [46][47] - **Other ADCs**: Competitors include Merck's CEACAM5 ADC and AbbVie's cMet ADC, but CytomX asserts that its drug has broader applicability due to the widespread expression of EpCAM [46][47] Combination Therapy Strategy - **Initial Combinations**: The company plans to start combination studies with bevacizumab and is considering other combinations to enhance treatment efficacy and expand market opportunities [49][50] - **Long-term Vision**: CytomX aims to replace traditional chemotherapy regimens, particularly irinotecan, with its ADC in earlier treatment lines [41][42] Additional Product Insights - **Other Asset**: CytomX is also developing a second product candidate, an interferon alpha-2b therapy for late-line melanoma, which is expected to be combined with KEYTRUDA [53] Conclusion - CytomX Therapeutics is positioned to address significant unmet needs in cancer treatment, particularly in CRC, with its innovative masked biologics technology and promising clinical data. The company is focused on expanding its clinical trials and exploring combination therapies to enhance treatment outcomes.

Core Viewpoint - Merck & Co., Inc. reported fourth-quarter results that met earnings expectations and slightly exceeded revenue forecasts, leading to a more than 2% increase in share price intraday [1] Group 1: Financial Performance - The company posted adjusted earnings per share of $2.04, aligning with analyst estimates [1] - Revenue increased by 5% year over year to $16.4 billion, surpassing the consensus estimate of $16.18 billion [1] Group 2: Growth Drivers - Growth was primarily driven by strong performance in oncology and animal health, along with contributions from newer products [2] - KEYTRUDA sales rose by 7% to $8.37 billion during the quarter [2] - Animal health revenue increased by 8% to $1.51 billion, supported by robust livestock demand [2] Group 3: Future Outlook - The 2026 outlook disappointed investors, with earnings forecasted at $5.00 to $5.15 per share, below analyst expectations of $5.63 [3] - A one-time charge of approximately $3.65 per share related to the acquisition of Cidara Therapeutics impacted the earnings forecast [3] - Revenue for 2026 is projected at $65.5 billion to $67.0 billion, slightly below the consensus of $67.58 billion [3] Group 4: Full-Year Sales - For the full year 2025, Merck reported worldwide sales of $65.0 billion, representing 1% growth, or 2% growth excluding foreign exchange [4] - KEYTRUDA generated $31.7 billion in annual sales [4] - Newer products WINREVAIR and CAPVAXIVE contributed $1.4 billion and $759 million, respectively [4]

Fourth-Quarter 2025 Sales and Earnings Merck & Co., Inc., Rahway, N.J., USA February 3, 2026 Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Question & Answer Session 2 Agenda Agenda Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., ...

Core Insights - Merck & Co., Inc. reported financial results for Q4 and full year 2025, highlighting a 5% increase in Q4 sales to $16.4 billion and a 1% increase in full-year sales to $65.0 billion, driven by strong demand for its innovative portfolio, particularly KEYTRUDA and new product launches [3][11][14] Financial Performance - Q4 2025 sales reached $16.4 billion, up from $15.6 billion in Q4 2024, marking a 5% increase [3] - Full-year sales for 2025 were $65.0 billion, compared to $64.2 billion in 2024, reflecting a 1% growth [11] - Non-GAAP EPS for Q4 2025 was $2.04, a 19% increase from $1.72 in Q4 2024, while full-year non-GAAP EPS was $8.98, up 17% from $7.65 in 2024 [30][11] Product Performance - KEYTRUDA sales in Q4 2025 were $8.4 billion, a 7% increase from $7.8 billion in Q4 2024, driven by strong global uptake in oncology [7] - GARDASIL sales declined by 34% in Q4 2025 to $1.0 billion, primarily due to lower demand in China and Japan [7] - Animal Health sales grew by 8% in 2025 to $6.4 billion, supported by higher demand for livestock products [16] Strategic Developments - The company completed the acquisition of Cidara Therapeutics for approximately $9.2 billion, enhancing its portfolio [37] - Merck announced positive late-stage trial results from 18 Phase 3 trials and initiated 21 new Phase 3 studies across various therapeutic areas [33] Regulatory and Pipeline Updates - The FDA approved KEYTRUDA and KEYTRUDA QLEX for the perioperative treatment of muscle-invasive bladder cancer [33] - The company is advancing its pipeline with significant regulatory milestones and ongoing studies in oncology, infectious diseases, and cardiometabolic areas [33][36] Future Outlook - For full-year 2026, Merck anticipates sales between $65.5 billion and $67.0 billion, with a non-GAAP effective tax rate expected between 23.5% and 24.5% [41][45] - Non-GAAP EPS for 2026 is projected to be between $5.00 and $5.15, including a one-time charge related to the acquisition of Cidara [46]

Market Overview - U.S. stock futures rose on Thursday following a more than 1% gain in major indices on Wednesday after President Trump withdrew tariff threats against the EU [1] - The 10-year Treasury bond yielded 4.24%, while the two-year bond was at 3.59%, with a 95% likelihood of unchanged interest rates projected for January [2] Index Performance - Dow Jones increased by 1.21% to 49,077.23 - S&P 500 rose by 1.16% to 6,875.62 - Nasdaq Composite gained 1.18% to 23,224.82 - Russell 2000 saw a 2.00% increase to 2,698.17 [10] Stocks in Focus - Intel Corp. (NASDAQ: INTC) was up 1.60% in premarket trading, projected to post quarterly earnings of 8 cents per share on revenue of $13.38 billion [7] - Microsoft Corp. (NASDAQ: MSFT) rose 1.06% after announcing a multiyear partnership with Mercedes-AMG PETRONAS F1 Team to integrate cloud and AI technologies [7] - Moderna Inc. (NASDAQ: MRNA) jumped 5.64% following positive updates on a cancer therapy study in collaboration with Merck & Co. Inc. [7] - The Metals Company Inc. (NASDAQ: TMC) gained 5.51% after a new rule by NOAA modernized regulations for deep-seabed mining permits [16] - Micron Technology Inc. (NASDAQ: MU) increased by 2.73% as CEO highlighted a memory chip shortage due to rising AI demand [16] Analyst Insights - BlackRock maintains a "pro-risk" investment stance for early 2026, driven by AI's transformative power and a supportive macroeconomic backdrop [11] - They expect the Federal Reserve to continue cutting interest rates, supported by a softening labor market and declining inflation [11] - BlackRock prefers equities over government bonds, keeping an underweight position on long-term U.S. Treasuries due to fiscal sustainability concerns [13]

Market Overview - U.S. stock futures rose on Thursday following a more than 1% gain in major indices on Wednesday after President Trump withdrew tariff threats against the EU [1] - The 10-year Treasury bond yielded 4.24%, while the two-year bond was at 3.59%, with a 95% likelihood of unchanged interest rates projected for January [2] Index Performance - Dow Jones increased by 1.21% to 49,077.23 - S&P 500 rose by 1.16% to 6,875.62 - Nasdaq Composite gained 1.18% to 23,224.82 - Russell 2000 saw a 2.00% increase to 2,698.17 [10] Stocks in Focus - Intel Corp. (NASDAQ: INTC) was up 1.60% in premarket trading, projected to post quarterly earnings of 8 cents per share on revenue of $13.38 billion [7] - Microsoft Corp. (NASDAQ: MSFT) rose 1.06% after announcing a multiyear partnership with Mercedes-AMG PETRONAS F1 Team to integrate cloud and AI technologies [7] - Moderna Inc. (NASDAQ: MRNA) jumped 5.64% following positive updates on a cancer therapy study in collaboration with Merck & Co. Inc. [7] - The Metals Company Inc. (NASDAQ: TMC) gained 5.51% after a new rule by NOAA modernized regulations for deep-seabed mining permits [16] - Micron Technology Inc. (NASDAQ: MU) increased by 2.73% as CEO highlighted a memory chip shortage due to rising AI demand [16] Analyst Insights - BlackRock maintains a "pro-risk" investment stance for early 2026, driven by AI's transformative power and a supportive macroeconomic backdrop [11] - They expect the Federal Reserve to continue cutting interest rates, supported by a softening labor market and declining inflation [11] - BlackRock prefers equities over government bonds, keeping an underweight position on long-term U.S. Treasuries due to fiscal sustainability concerns [13]

Group 1: High Roller Technologies Inc - High Roller Technologies Inc (NYSE:ROLR) shares increased by 29.6% to $10.21 in pre-market trading following the closure of its registered direct offering [1] - The company sold 1.89 million common shares at a price of $13.21 per share, generating approximately $25 million in gross proceeds before fees [1] Group 2: Other Stocks in Pre-Market Trading - iOThree Ltd (NASDAQ:IOTR) saw a significant gain of 80.2% to $5.28 in pre-market trading after a 12% increase on Wednesday [5] - American Rebel Holdings Inc (NASDAQ:AREB) rose 53.1% to $0.67 following the announcement of a 1-for-20 reverse stock split effective February 2 [5] - IO Biotech Inc (NASDAQ:IOBT) increased by 24.3% to $0.26 after announcing plans to explore strategic alternatives, including a merger or asset sale [5] - Moderna Inc (NASDAQ:MRNA) gained 5.5% to $52.54 after releasing five-year median follow-up data from a Phase 2b trial involving an mRNA-based neoantigen therapy [5] Group 3: Stocks Declining in Pre-Market Trading - Galaxy Payroll Group Ltd (NASDAQ:GLXG) fell 21.5% to $1.93 after a 12% decline on Wednesday [5] - Boxlight Corp (NASDAQ:BOXL) decreased by 18.7% to $1.48 after a 46% increase on Wednesday [5] - Pineapple Financial Inc (NYSE:PAPL) dropped 17% to $1.17 after a 46% jump on Wednesday following the release of first-quarter financial results [5]

Market Overview - The stock market experienced a significant rally due to positive developments in international trade, particularly the suspension of planned tariffs on EU countries by President Trump [1] - Major U.S. stock indexes saw notable gains, with the Dow Jones Industrial Average increasing by 1.2% to 49,077.23, the S&P 500 rising by 1.16% to 6,875.62, and the Nasdaq adding 1.18% to 23,224.82 [1] Company Highlights - **Intel Corporation (NASDAQ:INTC)**: - Intel's stock rose by 11.72% to close at $54.25, nearing its 52-week high of $54.41, with an after-hours gain of 1.2% to $54.92 [2] - Anticipation builds for Intel's fourth-quarter earnings report, expected to show earnings per share of 8 cents and revenue of $13.38 billion, following a previous quarter where revenue was $13.65 billion and earnings per share were 23 cents [3] - **Moderna Inc (NASDAQ:MRNA)**: - Moderna shares surged by 15.84% to $49.81, reaching a 52-week high of $50, with an after-hours increase of 4.4% to $52 [4] - Investor enthusiasm is driven by a recent update on a cancer therapy study in collaboration with Merck & Co, which showed significant improvements in recurrence-free survival for melanoma patients [5] - **The Metals Company Inc (NASDAQ:TMC)**: - TMC's stock climbed by 13.31% to $8.17, with an after-hours increase of 9.4% to $8.94 [6] - The company welcomed a new rule from the National Oceanic and Atmospheric Administration that modernizes regulations for deep seabed mining permits, aligning with TMC's strategy for transitioning to commercial production [7] - **Microsoft Corporation (NASDAQ:MSFT)**: - Microsoft's stock fell by 2.29% to $444.11, remaining below its 52-week high of $555.45 [8] - CEO Satya Nadella emphasized the need for artificial intelligence to deliver tangible benefits to maintain public trust, particularly in sectors like healthcare and education [8] - **Lucid Group Inc (NASDAQ:LCID)**: - Lucid's stock jumped by 17.88% to $11.47, with an expansion of its manufacturing partnership in Saudi Arabia enhancing its growth outlook [9] - The collaboration with Rockwell Automation aims to implement advanced manufacturing systems at Lucid's plant, providing real-time visibility and control over production lines [10]

Business Strategy & Pipeline - The company is transforming its portfolio with a focus on innovation, expecting over 20 new launches, most with blockbuster potential[9] - The company is actively pursuing science-driven business development transactions to create value[9] - The company has invested over $60 billion since 2021 in business development[47] Financial Outlook - The commercial opportunity from new growth drivers has increased to over $70 billion, reflecting substantial progress[9] - The mid-2030s revenue opportunity from potential new growth drivers is estimated to be over 2X the consensus 2028 total KEYTRUDA sales, representing approximately $35 billion[49] - Ten key programs represent 70% of the >$70 billion commercial opportunity[51] Key Approvals & Data Readouts in 2025 - Significant approvals were achieved in Oncology, including KEYTRUDA QLEX and KEYTRUDA in earlier-stage cancers[10, 14] - WINREVAIR received a PAH label update (ZENITH) in the Cardiometabolic area[11, 24] - ENFLONSIA was approved for RSV in Infectious Disease[12, 25] Pipeline Development & Milestones - Approximately 80 Phase 3 studies are ongoing[9] - Multiple Phase 3 readouts are anticipated through 2027 across novel mechanisms[59] - Strategic business development is driving an increase in the mid-2030s commercial opportunity[64]